Safety Endpoints: • Serious adverse events • Grade 3 or 4 CP-675,206-related adverse events • Immune-mediated adverse events • Hypersensitivity reactions to CP-675,206 as long as required [clinicaltrials_resource:c3a97abc2303a3f18d80ebc6745e91d0]

Safety Endpoints: • Serious adverse events • Grade 3 or 4 CP-675,206-related adverse events • Immune-mediated adverse events • Hypersensitivity reactions to CP-675,206 as long as required [clinicaltrials_resource:c3a97abc2303a3f18d80ebc6745e91d0]

Drug: CP-675,206 (Tremelimumab)
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:c3a97abc2303a3f18d80ebc6745e91d0

Safety Endpoints: • Serious adverse events • Grade 3 or 4 CP-675,206-related adverse events • Immune-mediated adverse events • Hypersensitivity reactions to CP-675,206 as long as required [clinicaltrials_resource:c3a97abc2303a3f18d80ebc6745e91d0]

Drug: CP-675,206 (Tremelimumab)
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:c3a97abc2303a3f18d80ebc6745e91d0
Bio2RDF identifier
c3a97abc2303a3f18d80ebc6745e91d0
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c3a97abc2303a3f18d80ebc6745e91d0
measure [clinicaltrials_vocabulary:measure]
Safety Endpoints: • Serious ad ...... tivity reactions to CP-675,206
time frame [clinicaltrials_vocabulary:time-frame]
description
Drug: CP-675,206 (Tremelimumab)
identifier
clinicaltrials_resource:c3a97abc2303a3f18d80ebc6745e91d0
title
Safety Endpoints: • Serious ad ...... CP-675,206 as long as required
@en
inDataset
type
label
Safety Endpoints: • Serious ad ...... 97abc2303a3f18d80ebc6745e91d0]
@en